Please use this identifier to cite or link to this item: http://www.repositorio.ufc.br/handle/riufc/19251
Title in Portuguese: Low-Dose naltrexone in diseases’ treatment : global review
Author: Moura, Felipe Carmo de
Martins, Conceição da Silva
Soares, Paula Matias
Brito, Gerly Anne de Castro
Keywords: Naltrexona
Antagonistas de Entorpecentes
Narcotic Antagonists
Issue Date: Feb-2016
Publisher: Research Inventy: International Journal of Engineering And Science
Citation: MOURA, F. C. de et al. Low-Dose naltrexone in diseases' treatment : global review. Research Inventy: International Journal of Engineering And Science, v. 6, n. 2, p. 1-4, feb., 2016.
Abstract: ABSTRACT – Naltrexone is a non - selective opioid antagonist, which shows effects on delta, mu and kappa rece ptors. Its therapeutic use is designed for drug addicts’ treatment, reducing withdrawal side effects. However, several researchers have used low - dose Naltrexone (LDN) for therapeutic purposes in diseases associated to immune system deficiency and inflammat ory and tumor processes. Consequently , enhance evidences that LDN use hypothesis promotes, through a compensation mechanism, an increase of endorphins and enkephalins, in addition to opioid receptors up - regulation mechanis m, in Central Nervous System (CNS) , becoming it a potentially effective clinical practice in these pathologies. Thus, we present a review about LDN use in different pathologies, all they published in literature, and its therapeutic effects, enabling us to conclude that 3.0 - 4.5mg/day dose u se in humans is effective for idiopathic diseases with alterations in immune system, as well as those ones with inflammatory and tumor characteristics
URI: http://www.repositorio.ufc.br/handle/riufc/19251
metadata.dc.type: Artigo de Periódico
ISSN: (p):2319 - 6483
(e): 2278 - 4721
Appears in Collections:PPGF - Artigos publicados em revistas científica

Files in This Item:
File Description SizeFormat 
2016_art_fcmoura.pdf453,1 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.